Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update ACCESSWIRE SON-1010, fully-human IL-12 configured using F HAB platform, advancing towards IND submission At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE / May 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ('Sonnet' or the 'Company'), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended March 31, 2021 and provided a business update. 'Over the course of the quarter, we have made several advancements across our pipeline products, most notably of which are the completion of non-human primate (NHP) toxicology study of SON-080 and the completion of a repeat dose study of SON-1010 in NHPs,' commented Pankaj Mohan, Ph.D., Founder and CEO. 'Additionally, we were thrilled to have our abstract detailing data from our NHP study of SON-1010 accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting.'